Noninvasive Ventilators and Airway Management Accessories
If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].
The two most common respiratory diseases, asthma and COPD, had prevalence rates of 53 million and 62 million in the US, five major European countries, and Japan in 2020. Global sales of positive-airway pressure (PAP)-based noninvasive ventilators and airway management accessories were estimated at $7.1bn in 2022. Market drivers include increasing awareness regarding the health benefits of CPAP therapy for the treatment of sleep apnea, automated CPAP devices that increase patient compliance, adoption of user-friendly app-based interfaces for changing CPAP settings and monitoring data, ongoing mask and accessory resupply for existing CPAP users, and increased demand for products to help maintain moist respiratory mucosa in patients with COVID-19 and other respiratory conditions. Limiters to this market include lack of patient compliance due to mask discomfort, and the integration of components such as humidifiers into CPAP devices, reducing sales of standalone devices.
This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for PAP-based noninvasive ventilators and airway management accessories; these include CPAP and BiPAP systems as well as heat/moisture exchangers, humidifiers, and nebulizers. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2022–27.
Related Medtech Insight articles:
- And The Hits Just Keep On Coming: Another Class I Recall For Philips Breathing Devices
- Teleflex Continues Restructuring By Selling Hudson Respiratory Business To Medline
- JPM 2023: Novocure Announces Trial Results; ResMed Expands Manufacturing; Abbott's IVD Bet Pays Off
- Subscribe to Medtech Insight to view these articles and more!